I wouldn't be surprised to see Q4 expenses be less than the $11.2m forecast for Q3.
Also we have the $2.5m tax rebate coming in.
Plus we'll have a proportion of that extra large overhang of receivables coming through.
Similarly, the new sales team and Vascucel/Neo sales will be turning into actual receipts received.
So I'm only expecting a small loss for Q4.
FY18 will then be - to quote Mendhelssohn - a calm sea and a prosperous voyage.
I wouldn't be surprised to see Q4 expenses be less than the...
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.31 |
Change
-0.240(1.29%) |
Mkt cap ! $351.9M | |||
| Open | High | Low | Value | Volume |
| $18.80 | $19.15 | $18.20 | $159.7K | 8.611K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 73 | $18.31 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.33 | 90 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| AVR (ASX) Chart |